Doseology Sciences, Inc.

As of March 31, 2026, Doseology Sciences Inc. carries a market capitalization of 5.40M, placing it among publicly traded companies globally. Its enterprise value stands at 5.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Doseology Sciences Inc. has 8.01M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 95.30, and the price-to-book ratio stands at 6.83.

These figures are as of March 31, 2026. The EV/Sales ratio of 88.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.14M versus a market cap of 5.40M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Doseology Sciences Inc. maintains a current ratio of 10.31, meaning it holds 10.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Doseology Sciences Inc. posted a negative return on equity (ROE) of -120.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -113.89, reflecting losses generated across the asset base. Inventory turnover of 0.73 indicates how many times Doseology Sciences Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on July 21, 2026, Doseology Sciences Inc.'s stock has declined approximately 89.08% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Doseology Sciences Inc. generated 58,405.96 in revenue and converted that into -840,634.80 in net income, yielding earnings per share of -0.10. EBITDA reached -854,476.23, while operating income came in at -854,476.23.

These figures are as of March 31, 2026. Total book value stands at 791,360.34, with working capital of 541,842.12 providing operational flexibility.

Doseology Sciences Inc. produced -837,061.01 in operating cash flow over the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Doseology Sciences Inc. posted a gross margin of 25.14, reflecting its pricing power and cost economics. The operating margin of -1,462.99 and net profit margin of -1,439.30 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -15.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Doseology Sciences Inc.'s most recent stock split took place on February 22, 2024 with a 10:1 split ratio.

As of March 31, 2026, Doseology Sciences Inc. has an Altman Z-Score of 39.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.